Mostrar el registro sencillo del ítem
Angiotensin receptor-neprilysin inhibition in patients with acute decompensated heart failure: an expert consensus position paper
dc.creator | Ntalianis A., Chrysohoou C., Giannakoulas G., Giamouzis G., Karavidas A., Naka A., Papadopoulos C.H., Patsilinakos S., Parissis J., Tziakas D., Kanakakis J. | en |
dc.date.accessioned | 2023-01-31T09:40:45Z | |
dc.date.available | 2023-01-31T09:40:45Z | |
dc.date.issued | 2022 | |
dc.identifier | 10.1007/s10741-021-10115-8 | |
dc.identifier.issn | 13824147 | |
dc.identifier.uri | http://hdl.handle.net/11615/77318 | |
dc.description.abstract | The short-term mortality and rehospitalization rates after admission for acute heart failure (AHF) remain high, despite the high level of adherence to contemporary practice guidelines. Observational data from non-randomized studies in AHF strongly support the in-hospital administration of oral evidence-based modifying chronic heart failure (HF) medications (i.e., b-blockers, ACE inhibitors, mineralocorticoid receptor antagonists) to reduce morbidity and mortality. Interestingly, a well-designed prospective randomized multicenter study (PIONEER-HF) showed an improved clinical outcome and stress/injury biomarker profile after in-hospital administration of sacubitril/valsartan (sac/val) as compared to enalapril, in hemodynamically stable patients with AHF. However, sac/val implementation during hospitalization remains suboptimal due to the lack of an integrated individualized plan or well-defined appropriateness criteria for transition to oral therapies, an absence of specific guidelines regarding dose selection and the up-titration process, and uncertainty regarding patient eligibility. In the present expert consensus position paper, clinical practical recommendations are proposed, together with an action plan algorithm, to encourage and facilitate sac/val administration during hospitalization after an AHF episode with the aim of improving efficiencies of care and resource utilization. © 2021, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. | en |
dc.language.iso | en | en |
dc.source | Heart Failure Reviews | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85105414137&doi=10.1007%2fs10741-021-10115-8&partnerID=40&md5=67eb4d2222b05cd529cb499fd0ad5341 | |
dc.subject | amino terminal pro brain natriuretic peptide | en |
dc.subject | angiotensin receptor antagonist | en |
dc.subject | beta adrenergic receptor blocking agent | en |
dc.subject | dipeptidyl carboxypeptidase inhibitor | en |
dc.subject | diuretic agent | en |
dc.subject | membrane metalloendopeptidase | en |
dc.subject | sacubitril plus valsartan | en |
dc.subject | aminobutyric acid derivative | en |
dc.subject | angiotensin derivative | en |
dc.subject | angiotensin receptor | en |
dc.subject | biphenyl derivative | en |
dc.subject | membrane metalloendopeptidase | en |
dc.subject | sacubitril | en |
dc.subject | acute heart failure | en |
dc.subject | clinical study | en |
dc.subject | consensus | en |
dc.subject | cost effectiveness analysis | en |
dc.subject | drug administration route | en |
dc.subject | forward heart failure | en |
dc.subject | health care utilization | en |
dc.subject | heart failure with reduced ejection fraction | en |
dc.subject | heart left ventricle ejection fraction | en |
dc.subject | hospital | en |
dc.subject | hospital discharge | en |
dc.subject | hospitalization | en |
dc.subject | human | en |
dc.subject | hyperkalemia | en |
dc.subject | hypotension | en |
dc.subject | kidney dysfunction | en |
dc.subject | patient care | en |
dc.subject | Review | en |
dc.subject | time to treatment | en |
dc.subject | unmet medical need | en |
dc.subject | heart failure | en |
dc.subject | heart stroke volume | en |
dc.subject | multicenter study (topic) | en |
dc.subject | prospective study | en |
dc.subject | randomized controlled trial (topic) | en |
dc.subject | treatment outcome | en |
dc.subject | Aminobutyrates | en |
dc.subject | Angiotensin Receptor Antagonists | en |
dc.subject | Angiotensins | en |
dc.subject | Biphenyl Compounds | en |
dc.subject | Consensus | en |
dc.subject | Heart Failure | en |
dc.subject | Humans | en |
dc.subject | Multicenter Studies as Topic | en |
dc.subject | Neprilysin | en |
dc.subject | Prospective Studies | en |
dc.subject | Randomized Controlled Trials as Topic | en |
dc.subject | Receptors, Angiotensin | en |
dc.subject | Stroke Volume | en |
dc.subject | Treatment Outcome | en |
dc.subject | Springer | en |
dc.title | Angiotensin receptor-neprilysin inhibition in patients with acute decompensated heart failure: an expert consensus position paper | en |
dc.type | other | en |
Ficheros en el ítem
Ficheros | Tamaño | Formato | Ver |
---|---|---|---|
No hay ficheros asociados a este ítem. |